Spero Therapeutics Inc (SPRO)
1.23
-0.08
(-6.11%)
USD |
NASDAQ |
Nov 14, 13:08
Spero Therapeutics Enterprise Value: 7.277M for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | 7.277M |
| November 12, 2024 | 7.818M |
| November 11, 2024 | 8.358M |
| November 08, 2024 | 7.818M |
| November 07, 2024 | 7.277M |
| November 06, 2024 | 7.277M |
| November 05, 2024 | 7.277M |
| November 04, 2024 | 6.196M |
| November 01, 2024 | 0.2509M |
| October 31, 2024 | 2.953M |
| October 30, 2024 | 6.196M |
| October 29, 2024 | 7.277M |
| October 28, 2024 | 6.196M |
| October 25, 2024 | 8.358M |
| October 24, 2024 | 4.575M |
| October 23, 2024 | 4.575M |
| October 22, 2024 | 5.115M |
| October 21, 2024 | 5.656M |
| October 18, 2024 | 5.656M |
| October 17, 2024 | 5.926M |
| October 16, 2024 | 3.494M |
| October 15, 2024 | 1.332M |
| October 14, 2024 | 2.953M |
| October 11, 2024 | 4.034M |
| October 10, 2024 | 3.494M |
| Date | Value |
|---|---|
| October 09, 2024 | 3.494M |
| October 08, 2024 | 3.494M |
| October 07, 2024 | 6.737M |
| October 04, 2024 | 6.737M |
| October 03, 2024 | 6.196M |
| October 02, 2024 | 7.277M |
| October 01, 2024 | 7.277M |
| September 30, 2024 | 8.899M |
| September 27, 2024 | 7.277M |
| September 26, 2024 | 5.656M |
| September 25, 2024 | 5.656M |
| September 24, 2024 | 5.656M |
| September 23, 2024 | 6.737M |
| September 20, 2024 | 8.358M |
| September 19, 2024 | 9.710M |
| September 18, 2024 | 8.899M |
| September 17, 2024 | 8.358M |
| September 16, 2024 | 10.52M |
| September 13, 2024 | 10.52M |
| September 12, 2024 | 8.358M |
| September 11, 2024 | 8.899M |
| September 10, 2024 | 9.439M |
| September 09, 2024 | 10.52M |
| September 06, 2024 | 7.548M |
| September 05, 2024 | 8.358M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-96.64M
Minimum
Jun 28 2022
527.97M
Maximum
Sep 23 2021
120.07M
Average
45.64M
Median
Nov 09 2022
Enterprise Value Benchmarks
| Arbutus Biopharma Corp | 563.85M |
| Equillium Inc | -5.654M |
| NovaBay Pharmaceuticals Inc | 3.432M |
| Palatin Technologies Inc | 13.74M |
| iBio Inc | 6.814M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.86M |
| Revenue (Quarterly) | 6.017M |
| Total Expenses (Quarterly) | 25.08M |
| EPS Diluted (Quarterly) | -0.33 |
| Profit Margin (Quarterly) | -296.9% |
| Earnings Yield | 27.64% |
| Operating Earnings Yield | 31.65% |
| Normalized Earnings Yield | 34.11 |